Britain and Germany are pioneering comparative reviews of drugs' effectiveness and cost-benefit analyses aimed at reimbursing firms for new drugs based on how well they perform.
Two years ago, a panel rejected Xinlay, a prostate cancer drug from Abbott Laboratories, because the only evidence for its effectiveness came from after-the-fact analyses of two clinical trials.